Author Correction: Glucose and fatty acid metabolism involved in the protective effect of metformin against ulipristal-induced endometrial changes in rats

The original Figure 4 and accompanying legend appear below. Figure 4 Effect of metformin or/and ulipristal on the expression of the proliferation markers of rats’ uteri. ( A – D ) photomicrographs of uteri shows expression of PCNA ( A ) Uterine wall in the control group. ( B ) Uterine wall in ulipristal treated group. ( C ) Uterine wall in metformin treated group. ( D ) Uterine wall in the ulipristal and metformin treated group. × 400 magnification (scale bar = 20 μm). ( E ) Expression quantification of the optical density reactivity of positive cells of PCNA by the ImageJ analysis system. ( F ) Quantitative RT-PCR analysis of PCNA mRNA expression. ( G – J ) Photomicrographs of uteri shows expression of Cyclin-D. ( G ) Uterine wall in the control group. ( H ) Uterine wall in ulipristal treated group. (I) Uterine wall in metformin treated group. ( J ) Uterine wall in the ulipristal and metformin treated group. × 400 magnification (scale bar = 20 μm). ( K ) Expression quantification of the optical density reactivity of positive cells by the ImageJ analysis system. ( L ) Quantitative RT-PCR analysis of Cyclin D1 mRNA expression, Black arrow refers to reactivity in endometrial glands, red arrows refers to reactivity in stromal cells. Data in figures ( E ) and ( K ) is represented by mean ± SD (n = 7). All value of RT-PCR is expressed as the change in cycle threshold (ΔCt). Each dot represents mean of each group (n = 7, triplicate for each rat). Negative control (DEPC-treated water) showed no detectable fluorescent signals. a or b, Statistically significant from the control or ulipristal and metformin treated group respectively at P < 0.05 using one-way ANOVA followed by Tukey as a post hoc test. UPA ulipristal, MET metformin, UPA + MET co-treatment with ulipristal and metformin. Full size image